Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MECOM/EVI1 Characterization in AML
NCT05839392Recruiting
- Sponsor
- GIMEMA
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Single-arm trial, sponsored by GIMEMA. Primary endpoint: Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable. Started Dec 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05839392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839392.